HK1042306A1 - Hexapeptide with the stabilized disulfide bond andderivatives thereof regulating metabolism, prolif eration, differententiation and apoptosis. - Google Patents

Hexapeptide with the stabilized disulfide bond andderivatives thereof regulating metabolism, prolif eration, differententiation and apoptosis.

Info

Publication number
HK1042306A1
HK1042306A1 HK02101786A HK02101786A HK1042306A1 HK 1042306 A1 HK1042306 A1 HK 1042306A1 HK 02101786 A HK02101786 A HK 02101786A HK 02101786 A HK02101786 A HK 02101786A HK 1042306 A1 HK1042306 A1 HK 1042306A1
Authority
HK
Hong Kong
Prior art keywords
differententiation
andderivatives
hexapeptide
apoptosis
disulfide bond
Prior art date
Application number
HK02101786A
Other languages
English (en)
Inventor
Leonid Andreevich Kozhemyakin
Andrei Leonidovich Kozhemyakin
Mark Borisovich Balazovsky
Original Assignee
Novelos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novelos Therapeutics Inc filed Critical Novelos Therapeutics Inc
Publication of HK1042306A1 publication Critical patent/HK1042306A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
HK02101786A 1998-11-23 2002-03-08 Hexapeptide with the stabilized disulfide bond andderivatives thereof regulating metabolism, prolif eration, differententiation and apoptosis. HK1042306A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU98120753/14A RU2144374C1 (ru) 1998-11-23 1998-11-23 Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
RU99105585/14A RU2153350C1 (ru) 1998-11-23 1999-03-26 Композит гексапептида со стабилизированной дисульфидной связью с веществом металлом, фармацевтические композиции на его основе, способы их получения и применения для лечения заболеваний на основе регуляции метаболизма, пролиферации, дифференцировки и механизмов апоптоза в нормальных и патологически измененных тканях
PCT/RU1999/000453 WO2000031120A2 (en) 1998-11-23 1999-11-19 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis

Publications (1)

Publication Number Publication Date
HK1042306A1 true HK1042306A1 (en) 2002-08-09

Family

ID=26653985

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101786A HK1042306A1 (en) 1998-11-23 2002-03-08 Hexapeptide with the stabilized disulfide bond andderivatives thereof regulating metabolism, prolif eration, differententiation and apoptosis.

Country Status (14)

Country Link
US (1) US7169412B2 (zh)
EP (1) EP1131340B1 (zh)
JP (1) JP3547400B2 (zh)
CN (1) CN1371388A (zh)
AP (1) AP2001002147A0 (zh)
AT (1) ATE279431T1 (zh)
AU (1) AU2582800A (zh)
CA (1) CA2351354A1 (zh)
DE (1) DE69921175T2 (zh)
ES (1) ES2233100T3 (zh)
HK (1) HK1042306A1 (zh)
OA (1) OA11714A (zh)
RU (2) RU2144374C1 (zh)
WO (1) WO2000031120A2 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144374C1 (ru) 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6534540B2 (en) 2000-10-06 2003-03-18 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
KR101327660B1 (ko) * 2004-10-05 2013-11-12 아이노벡스 가부시키가이샤 정신 증상의 치료 또는 예방용 조성물 및 방법
EA009610B1 (ru) * 2005-12-07 2008-02-28 Леонид Андреевич Кожемякин Средство для профилактики и лечения ринитов различной этиологии, способ его получения, фармацевтическая композиция на его основе, способ профилактики и лечения
EA010926B1 (ru) * 2006-01-20 2008-12-30 Леонид Андреевич Кожемякин Средство для лечения туберкулеза глаз, способ его получения и применения
JP4640996B2 (ja) * 2006-03-22 2011-03-02 株式会社興人 還元型グルタチオンの製造方法
JP4640997B2 (ja) * 2006-03-22 2011-03-02 株式会社興人 還元型グルタチオンの製造法
US8105233B2 (en) * 2007-10-24 2012-01-31 Tarek Ahmed Nabil Abou El Kheir Endoscopic system and method for therapeutic applications and obtaining 3-dimensional human vision simulated imaging with real dynamic convergence
CN101917976B (zh) * 2007-11-20 2013-08-28 兰肯瑙医学研究所 二硫化物化疗药及其在制备癌症治疗的药物中的应用
EA014044B1 (ru) * 2008-07-09 2010-08-30 Общество С Ограниченной Ответственностью "Аква-Альянс" Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты)
WO2010132771A1 (en) 2009-05-15 2010-11-18 Lankenau Institute For Medical Research Methods and kits for measuring toxicity and oxidative stress in live cells
RU2417999C2 (ru) * 2009-07-13 2011-05-10 Закрытое Акционерное Общество "Ива Фарм" БИЯДЕРНЫЕ КООРДИНАЦИОННЫЕ СОЕДИНЕНИЯ БИОЛОГИЧЕСКИ АКТИВНЫХ d-ЭЛЕМЕНТОВ С АЛИФАТИЧЕСКИМИ ТИОЛАМИ КАК СРЕДСТВА ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
CN107011131B (zh) * 2010-08-30 2020-11-10 味之素株式会社 含有支链的芳香族化合物
EP2444522B1 (en) * 2010-10-21 2017-04-05 Rohm and Haas Electronic Materials LLC Stable nanoparticles for electroless plating
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
BR112013031550B1 (pt) * 2011-06-30 2022-01-18 Kaneka Corporation Sal de glutationa oxidada, formulações e método para produzir o mesmo
RU2482869C1 (ru) * 2011-12-30 2013-05-27 Общество С Ограниченной Ответственностью "Ива Фарм" Гемостимулирующее средство, фармацевтическая композиция и способ стимулирования гемопоэза
RU2482868C1 (ru) * 2011-12-30 2013-05-27 Общество С Ограниченной Ответственностью "Ива Фарм" Средство для лечения диабета, фармацевтическая композиция и способ лечения заболеваний
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
RU2659161C1 (ru) * 2017-11-17 2018-06-28 Общество С Ограниченной Ответственностью "Ива Фарм" Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
IT1176983B (it) 1984-10-16 1987-08-26 Zambon Spa Dipeptidi ad attivita' farmacologica
JPH075631B2 (ja) 1986-03-19 1995-01-25 参天製薬株式会社 グルタチオン誘導体
WO1988000182A1 (en) * 1986-07-07 1988-01-14 Teijin Limited gamma-L-GLUTAMYL-L-CYSTEINE ETHYL ESTER AND DRUG CONTAINING IT AS EFFECTIVE INGREDIENT
ES2036553T3 (es) * 1986-10-07 1993-06-01 Boehringer Mannheim Italia S.P.A. Composiciones farmaceuticas que tienen actividad antineoplastica.
US6030950A (en) * 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US4968671A (en) 1987-11-26 1990-11-06 Yamanouchi Pharmaceutical Co., Ltd. Therapeutic agents for ischemic heart diseases
US5104852A (en) * 1989-02-27 1992-04-14 The Ohio State University Method for the inhibition of the proliferation of cancer cells in a tumor sensitive to treatment with a selenodithiol by the injection into the tumor of a selenodithiol such as selenodiglutathione
US5206220A (en) * 1990-04-23 1993-04-27 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition
JPH049336A (ja) 1990-04-26 1992-01-14 Yasuo Komoda 催眠剤
US5248697A (en) * 1990-09-20 1993-09-28 Brigham And Women's Hospital Enhancement of glutathione levels with glutamine
JP2921124B2 (ja) * 1990-12-28 1999-07-19 千寿製薬株式会社 酸化型グルタチオンアルキルエステル
DE69220821T2 (de) 1991-02-04 1997-11-20 Nestle Sa Verfahren zur Sicherstellung eines angemessenen intrazellulären Glutathionspiegels im Gewebe
US5977073A (en) 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
US5352771A (en) * 1992-08-31 1994-10-04 Iowa State University Research Foundation Inc. Hydrolysis of peptide bonds using Pt (II) and Pd (II) complexes
GB9303854D0 (en) 1993-02-25 1993-04-14 Holt John A G Method for enhancing t-cell count
SE9403526D0 (sv) * 1994-10-14 1994-10-14 Astra Ab New Peptides
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5627152A (en) * 1995-01-18 1997-05-06 Telluride Pharmaceutical Corporation Method for increasing bodyweight
SE9501067D0 (sv) * 1995-03-24 1995-03-24 Astra Ab New peptides
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
ATE280582T1 (de) 1995-06-07 2004-11-15 Telik Inc Stoffwechseleffekt von bestimmten glutation analogen
EP0764442A1 (en) 1995-09-19 1997-03-26 John Alfred Gorton Holt Use of specific sulphur containing aminos acid derivatives against pathogenic viral or prion particles
US5916878A (en) 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
ATE214936T1 (de) * 1995-12-14 2002-04-15 Novelos Therapeutics Inc Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
US5994402A (en) * 1996-06-05 1999-11-30 Rotstein; Ori D. Anti-inflammatory and anti-pyretic method
JP4002313B2 (ja) 1996-08-21 2007-10-31 株式会社ノエビア 皮膚外用剤
CA2276183C (en) * 1996-12-31 2009-06-09 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US6013632A (en) * 1997-01-13 2000-01-11 Emory University Compounds and their combinations for the treatment of influenza infection
WO1999055326A1 (en) * 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
CN1681558A (zh) 2002-09-11 2005-10-12 得克萨斯州大学系统董事会 作为抗肿瘤剂的铂复合物与生物化学调节剂的组合

Also Published As

Publication number Publication date
DE69921175T2 (de) 2005-06-30
CA2351354A1 (en) 2000-06-02
JP3547400B2 (ja) 2004-07-28
US20050054580A1 (en) 2005-03-10
ATE279431T1 (de) 2004-10-15
WO2000031120A3 (en) 2000-10-26
US7169412B2 (en) 2007-01-30
CN1371388A (zh) 2002-09-25
DE69921175D1 (de) 2004-11-18
OA11714A (en) 2005-01-18
AU2582800A (en) 2000-06-13
EP1131340B1 (en) 2004-10-13
AP2001002147A0 (en) 2001-06-30
JP2002538079A (ja) 2002-11-12
WO2000031120A2 (en) 2000-06-02
RU2153350C1 (ru) 2000-07-27
RU2144374C1 (ru) 2000-01-20
ES2233100T3 (es) 2005-06-01
EP1131340A2 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
HK1042306A1 (en) Hexapeptide with the stabilized disulfide bond andderivatives thereof regulating metabolism, prolif eration, differententiation and apoptosis.
AU5130299A (en) Wrist-mounted i.v. administration set
HK1041947A1 (en) Scheduling instructions with different latencies.
ZA986308B (en) The induction of stress-related factors in plants.
ZA976003B (en) Icing set.
HK1041702A1 (zh) 取代的2-苯基苯並咪唑類，其製備和用途
ZA982356B (en) Food fortification.
ZA984647B (en) Dextran production.
ZA97944B (en) N: 1 Transcoder.
ZA9811070B (en) Type I interferons.
ZA988637B (en) Methods for regulating trkA expression.
Chomsky Comments: Galen Strawson, Mental Reality
EP1090992A4 (en) NEW POLYPEPTIDE, DNA CODING IT, AND ITS USE
ZA986160B (en) 2,4,4-trisubstituted-1,3-dioxolone antifungals.
Sunstein et al. The Supreme Court, 1995 Term
EP1104771A4 (en) NEW POLYPEPTIDES, cDNA encoding THEREOF AND USE THEREOF
Basic Version1. 0
ZA991592B (en) Pumping plant.
Hewett Into the daylight
Mellers Up and down the Aisle
Wilson Subglacial conditions associated with the Laurentide, Lac La Biche ice stream
Reinhart The first Billion
IT242471Y1 (it) Suola traspirante con valvola di sola mandata sul battistrada.
AUPP649098A0 (en) The double loop
EP1053251A4 (en) GENE AIOLOS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111119